1. Tailoring Therapy in the Newly Diagnosed Patient With CLL

3. New Therapies/Indications for CLL

4. Case 1: A 59-Year-Old Man

5. Case 1 (cont)

6. FISH Testing in CLL

7. FCR in Patients With del(17p)

8. BR as First-Line Therapy

9. Mechanism of del(17p) in CLL

10. Novel Agents for Patients With del(17p)

11. Efficacy of Ibrutinib in 17p

12. Testing for TP53 Mutations

13. Ibrutinib: Efficacy by Treatment History

14. Trial of First-Line Idelalisib

15. Efficacy of Idelalisib in del(17p)

16. Safety Concerns With Idelalisib

17. Phase 2 Trial of Venetoclax in del(17p)

18. Case 2: A 65-Year-Old Man

19. CLL10: First-Line FCR vs BR

20. CLL10: Outcomes Stratified by Age

21. Phase 3 Intergroup Studies

22. Case 3: A 79-Year-Old Woman

23. RESONATE-2: Ibrutinib vs Chlorambucil

24. CLL11: Study Design

25. CLL11: Efficacy Outcomes

26. Infusion Reactions With Obinutuzumab

27. CLL11: Updated Results

28. Ongoing Studies of Combinations

29. Summary

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)